Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12667071 | 0.90 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL24305870 | 0.85 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL18913220 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL12674679 | 0.80 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL17545698 | 0.80 | SCN9A (0.35) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL26081381 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL593099 | 0.79 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL15958788 | 0.79 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL26190602 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| Ammonia Solution, Strong SCHEMBL16105230 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8808961-B2 | Composition, resist film, pattern forming method, and inkjet recording method | FUJIFILM CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20110102528-A1 | COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110102528-A1 | COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND INKJET RECORDING METHOD | ARFGAP1, FRG1, RHOA | ALDH1A1 659/4885MEN1 599/4885KMT2A 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.